Vor Biopharma (NASDAQ:VOR) Trading 8.3% Higher – Here’s What Happened

Vor Biopharma Inc. (NASDAQ:VOR)’s share price traded up 8.3% on Wednesday . The stock traded as high as $15.32 and last traded at $15.2650. 392,838 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 986,901 shares. The stock had previously closed at $14.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush boosted their target price on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Trading Down 0.0%

The firm has a 50-day moving average of $15.13 and a two-hundred day moving average of $13.63.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Equities analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the transaction, the director directly owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. The trade was a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 3,002,903 shares of company stock worth $49,412,176 over the last quarter. 0.45% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VOR. China Universal Asset Management Co. Ltd. acquired a new position in Vor Biopharma during the fourth quarter valued at $36,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd acquired a new position in Vor Biopharma during the second quarter valued at $66,000. Chung Wu Investment Group LLC acquired a new position in Vor Biopharma during the fourth quarter valued at $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma in the 4th quarter worth about $134,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).